Winship Cancer Institute to host preceptorship
The Winship Cancer Institute at Emory University in Atlanta, Georgia, has announced a program to provide educational exposure for early- to mid-career practicing oncologists from Brazil, Argentina, Mexico, and Colombia.
Observers will learn the optimal genomically-driven management of patients with lung cancer and breast cancer. The preceptorship is a deep immersion program during a 2-week period.
This year’s sessions will take place August 12-28 and October 14-30. Accommodation expenses and round-trip travel to the United States, including visa application fees, will be covered by the program. Health insurance and a stipend to cover a reasonable cost of living including meals will be provided to trainees for the duration of the program.
For more information, visit winshipcancer.emory.edu/preceptorship-latin-america or contact Barbara Powley at [email protected].
NICE recommends tepotinib for advanced NSCLC with METex14 skipping gene alterations
The United Kingdom’s National Institute for Health and Care Excellence (NICE) has recommended tepotinib for the treatment of certain adult patients in the UK with advanced NSCLC.
In its recommendation, the institute said tepotinib is an innovative and potentially life-extending drug for treating people with METex14 skipping gene alterations. While only 1-2% of adult lung cancer patients in England have this alteration, the recommendation has the potential to benefit more than 700 people, according to the organization.
Have news to share? Email [email protected].
